• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    STAAR Surgical Stock Faces Mixed Q3 Sales After Return To Profitability

    Simply Wall St·11/09/2026 10:24:59
    Listen to the news
    • STAAR Surgical reported third quarter 2026 results with sales of US$83.41 million and net income of US$5.58 million, alongside basic and diluted EPS of US$0.11.
    • Across the first nine months of 2026, STAAR Surgical generated US$270.47 million in sales and US$18.84 million in net income, indicating a shift from the prior year loss.
    • The focus now turns to how STAAR Surgical's return to profitability over nine months may influence the investment narrative around its refractive lens business.

    Scan how STAAR Surgical stacks up against other potential breakouts in refractive care and broader medical devices by reviewing the hand picked 19 high quality undiscovered gems.

    STAAR Surgical Investment Narrative Recap

    To own STAAR Surgical, you need to believe its refractive lens portfolio can turn today’s profitability into something repeatable while it works through mixed quarterly demand. The third quarter showed lower sales and earnings than the same period last year, so short term conviction hangs on whether management can stabilise volumes without leaning on heavy one off items.

    The analyst consensus Narrative on Simply Wall St leans on catalysts like China mix, U.S. underpenetration and cost discipline. The biggest swing factor near term is execution on those operational targets, while the key risk is that muted China demand or delayed cost improvement keeps margins and cash generation from building meaningfully.

    The return to profit across the first nine months of 2026, after a prior year loss, is the announcement that matters most here. It shows STAAR Surgical producing US$18.84 million in net income with positive EPS, even though quarterly results remain choppy and still affected by earlier one off items in the reported period.

    For catalysts, that nine month profitability lines up with the Narrative that focuses on operating leverage as revenue builds on the existing platform and the Nidau, Switzerland ramp aims to relieve tariff and unit cost pressure. The risk is straightforward for you as a shareholder. If that operational follow through slows, the current valuation multiples leave less room for disappointment.

    STAAR Surgical's narrative points to revenues of US$416.6 million and earnings of US$41.5 million by 2029, which lines up with analyst assumptions of 7.0% yearly revenue growth and an earnings increase of about US$37.7 million from US$3.8 million today.

    Uncover how STAAR Surgical's fair value indicates an 11% potential upside to its current price before the market closes that valuation gap.

    NasdaqGM:STAA 1-Year Stock Price Chart
    NasdaqGM:STAA 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view on STAAR Surgical focuses on concentration risk in China. The most cautious analysts were only pencilling in about US$376.8 million of revenue and US$28.2 million of earnings by 2029, so they see far less upside. Your view of today’s earnings could easily shift which story feels more realistic.

    Explore 2 other STAAR Surgical fair value estimates, including one that suggests it could be worth just $28.00.

    Reach Your Own Conclusion

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking For More Ideas Beyond STAAR Surgical?

    If STAAR Surgical has sharpened your focus on refractive care and medical devices, it can be useful to widen the lens and compare it with other opportunities that fit different objectives for risk, income, or valuation. The Simply Wall St Screener gives you a structured way to surface companies that match the type of profile you are looking for instead of relying on headlines or hunches.

    • If you want potential value opportunities with quality fundamentals, scan the 40 high quality undervalued stocks that combine earnings strength with comparatively low valuations.
    • For a focus on capital preservation and smoother ride potential, filter for companies in the 31 resilient stocks with low risk scores that score well on risk metrics and balance sheet resilience.
    • Income focused investors can zero in on cash return potential by reviewing the 7 dividend fortresses that offer higher yields with an emphasis on durability.